Clinical Trial: A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic Function

U.S., Feb. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07428525) titled 'A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic Function' on Feb. 19.

Brief Summary: The primary objective of the trial is to evaluate the pharmacokinetics (PK) of AMG 133 after a single subcutaneous (SC) dose in participants with mild, moderate, or severe hepatic impairment compared to participants with normal hepatic function.

Study Start Date: March 14, 2025

Study Type: INTERVENTIONAL

Condition: Hepatic Impairment

Intervention: DRUG: AMG 133

Participants will receive AMG 133 SC.

Recruitment Status: ACTIVE_NOT_RECRUITING

Sponsor: Amgen

Published by HT Digital Conte...